Deerfield Capital

The Oncology Institute of Hope and Innovation is a prominent community oncology practice in the United States, recognized for its comprehensive and integrated cancer care services. Established in 2007 and headquartered in Cerritos, California, the organization operates over 50 clinic locations across California, Arizona, and Nevada, employing more than 500 staff members, including over 80 physicians and advanced practice providers. The Oncology Institute specializes in cancer awareness, prevention, diagnosis, and treatment, offering services such as chemotherapy education, lab testing, pain management, and dietary counseling. It also features in-house facilities including an infusion center, pharmacy, and support groups, as well as the Hope, Health, and Healing Center, which provides alternative and holistic treatments. Additionally, the institute conducts clinical trials and provides educational seminars, aiming to deliver evidence-based care to over 1 million patients, thereby enhancing access to specialized oncology services in community settings.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

Singular Genomics is a life science technology company that develops innovative sequencing platforms. Its core product, the Singular Sequencing Engine, powers two integrated solutions: G4 for next-generation sequencing (NGS) markets, offering high accuracy and speed; and PX, which combines single-cell analysis, spatial analysis, genomics, and proteomics in one versatile multi-omics instrument. These products aim to empower researchers and clinicians across diverse fields such as basic biology, oncology, immunology, and more.

Lomond Therapeutics is a pharmaceutical firm that discovers and develops small molecule inhibitors that target escape variants in hematologic malignancies.

Elion Therapeutics is a biotechnology company dedicated to developing innovative treatments for life-threatening systemic fungal infections. The company focuses on enhancing the efficacy of Amphotericin B, a well-known antifungal drug, while ensuring that its formulations remain non-toxic to mammalian cells. By leveraging mechanistic insights, Elion aims to optimize natural compounds to create a broad spectrum of safe and effective antifungal therapies. Through its clinical research and development services, Elion Therapeutics is committed to addressing the urgent medical needs posed by invasive fungal infections.

Relation Therapeutics is a biotechnology company focused on advancing drug discovery and development. It utilizes human genetics and clinical omics data, alongside patient-derived tissue samples, to identify and validate therapeutic programs. The company employs machine learning to explore the relationships between genes, proteins, and drugs, generating insights that have real translational validity. By combining single-cell multi-omics from patient tissues with functional assays, Relation Therapeutics aims to deepen the understanding of biological processes in human health and disease. This approach enables healthcare providers to discover and develop novel treatments, particularly in areas with unmet medical needs.

BiomX Inc. is a clinical-stage company based in Ness Ziona, Israel, focused on developing bacteriophage-based therapies aimed at treating and preventing diseases linked to microbiome imbalances. The company’s innovative approach targets harmful bacteria associated with various conditions, including skin issues and chronic diseases such as inflammatory bowel disease, colorectal cancer, and primary sclerosing cholangitis. Its lead product candidates include BX001, aimed at improving skin appearance, and BX002, a therapeutic phage for inflammatory bowel disease. Additional candidates such as BX003 and BX004 target bacteria associated with liver disorders and chronic pulmonary infections, respectively. BiomX collaborates with esteemed institutions, including the Weizmann Institute of Science and MIT, to leverage cutting-edge research in microbiome modulation. Founded in 2015, BiomX is dedicated to advancing microbiome therapeutics through its robust development pipeline.

Frontier Medicines Corporation, established in 2018 and headquartered in South San Francisco, California, is a pre-clinical stage biopharmaceutical company specializing in cancer research. The company employs chemoproteomics to discover and develop novel medicines targeting cancer-causing proteins. Frontier Medicines' innovative platform integrates advanced computational methods and machine learning algorithms to identify and pharmacologically target new binding pockets on proteins, thereby enabling small-molecule drug discovery and development for previously inaccessible targets.

Kura Oncology is a clinical-stage biopharmaceutical company based in San Diego, California, focused on developing targeted therapies for cancer treatment. The company’s primary product candidate, Tipifarnib, is an orally available farnesyl transferase inhibitor currently undergoing Phase II clinical trials for solid tumors, peripheral T-cell lymphomas, and various hematologic malignancies. In addition to Tipifarnib, Kura is advancing other small molecule candidates, including KO-947, which targets dysregulated extracellular signal-related kinases, and KO-539, aimed at inhibiting the menin-mixed lineage leukemia protein interaction. Kura Oncology emphasizes precision medicine, leveraging insights from cancer genomics to create targeted treatments for patients with specific genetic profiles, addressing significant unmet medical needs across various cancer types, including lung, colorectal, thyroid, pancreatic cancers, and blood cancers such as lymphoma and leukemia. The company was founded in 2014 and operates primarily within the United States.

CalciMedica, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, specializing in the discovery and development of small molecule drugs aimed at treating autoimmune and inflammatory diseases. Founded in December 2006 by a team of scientists with backgrounds in the field, the company focuses on the specific inhibition of calcium release-activated calcium channels. This innovative approach seeks to modulate the immune response and protect against tissue cell injury, addressing significant unmet medical needs in life-threatening inflammatory conditions for which existing therapies are lacking. CalciMedica's proprietary technology has the potential to offer therapeutic benefits in these challenging areas of healthcare.

Actio Biosciences specializes in developing precision medicines tailored to homogeneous rare patient populations. Its pipeline focuses on creating new drugs designed to enhance clinical success rates and ultimately deliver treatments to all patients in need, including those with challenging-to-cure illnesses.

Valneva is a biopharmaceutical company specializing in the development, manufacturing, and distribution of prophylactic vaccines for infectious diseases. Its portfolio comprises two commercially available vaccines (IXIARO/JESPECT for Japanese encephalitis and DUKORAL for traveler's diarrhea), along with vaccine candidates targeting Lyme disease, chikungunya virus, and COVID-19. Valneva operates through segments including Commercialized Vaccines, Covid-19 Vaccine, Vaccine Candidates, and Technologies & Services. The company aims to address significant unmet medical needs in infectious diseases by leveraging its expertise and capabilities to advance vaccine candidates through clinical trials and ultimately commercialize them.

Adaptive Phage Therapeutics, Inc. is a clinical-stage company focused on addressing the global challenge posed by multi-drug resistant (MDR) pathogenic bacteria. Founded in 2016 and headquartered in Gaithersburg, Maryland, the company offers therapeutic solutions utilizing its PhageBank, a comprehensive collection of bacteriophages—viruses that specifically target harmful bacteria. Through an advanced system for matching these phages to the unique bacterial infections of patients, Adaptive Phage Therapeutics aims to enable medical researchers to create effective treatments that can detect and combat MDR infections.

Bitterroot Bio is a biotechnology company focused on developing innovative therapies for cardiovascular disease by harnessing the immune system's natural capabilities. The company conducts research to uncover the essential roles of immune cells and immune modulators in the onset and progression of cardiovascular conditions. By leveraging immunotherapy, Bitterroot Bio aims to create and deliver novel medicines that can significantly improve treatment options for patients suffering from these diseases, thereby transforming the landscape of cardiovascular care.

Ascend Gene & Cell Therapies supports manufacturing and process development projects from design through to clinical and commercial scales. They partner with biotechnology teams to embed scalable manufacturing in their operations from the beginning. They respond to customer inquiries by phone and contact form.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through the development of highly sensitive tests that identify and characterize circulating tumor cells (CTCs) using minimally invasive blood samples. Founded in 2008, the company’s platform enables the profiling of single-cell phenotypes and genotypes, providing detailed information on biomarker expression levels, morphologic characteristics, and genetic changes. Epic Sciences offers the Oncotype DX AR-V7 Nucleus Detect test specifically for patients with metastatic castration-resistant prostate cancer, as well as biopharma solutions. The company collaborates with biotechnology and pharmaceutical firms, major cancer centers, and renowned research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and guide treatment decisions.

Abivax is a clinical-stage biotechnology company based in France, dedicated to developing innovative therapeutics that leverage the body's natural immune mechanisms to treat patients with autoimmune diseases, viral infections, and cancer. The company's primary focus is on chronic inflammatory diseases, particularly inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Abivax is currently evaluating its leading drug candidate, obefazimod, in Phase 3 clinical trials aimed at addressing moderately to severely active ulcerative colitis. Through its drug development platforms, Abivax strives to deliver novel and effective treatments to patients with significant unmet medical needs in these therapeutic areas.

Vicinitas Therapeutics is a biotech startup that specializes in developing medicines that impact patient lives. Its vision is to use its proprietary Deubiquitinase Targeting Chimera (DUBTAC) platform to restore the levels of aberrantly degraded proteins that cause disease to confer therapeutic benefit.

Humanity Health is a platform dedicated to advancing the careers of underrepresented leaders in healthcare and life sciences. By leveraging best-in-class technology and a personalized service approach, the company creates career-accelerating opportunities for women and people of color. It aids employer partners in identifying, engaging, and recruiting diverse healthcare talent, thus fostering more inclusive hiring practices. A key component of Humanity Health is its Humanity Talent Network, a private membership network that amplifies and supports experienced leaders from underrepresented backgrounds. This network focuses on enhancing access to competitive executive positions, board roles, and entrepreneurial ventures, ultimately contributing to a more equitable landscape within the healthcare and life sciences sectors.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through the development of highly sensitive tests that identify and characterize circulating tumor cells (CTCs) using minimally invasive blood samples. Founded in 2008, the company’s platform enables the profiling of single-cell phenotypes and genotypes, providing detailed information on biomarker expression levels, morphologic characteristics, and genetic changes. Epic Sciences offers the Oncotype DX AR-V7 Nucleus Detect test specifically for patients with metastatic castration-resistant prostate cancer, as well as biopharma solutions. The company collaborates with biotechnology and pharmaceutical firms, major cancer centers, and renowned research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and guide treatment decisions.

UTR Therapeutics Inc is a biotechnology company focused on developing treatments for aggressive cancers driven by the overexpression of the c-MYC gene. The company, spun out from City University of New York and Harvard Medical School, specializes in researching and developing therapeutics that target and degrade specific gene transcripts involved in tumor progression. Their primary focus is on cancers like triple negative breast cancer, medulloblastoma, and osteosarcoma, aiming to provide clinicians with treatments that directly act on cancer-causing genetic expressions.

Valneva is a biopharmaceutical company specializing in the development, manufacturing, and distribution of prophylactic vaccines for infectious diseases. Its portfolio comprises two commercially available vaccines (IXIARO/JESPECT for Japanese encephalitis and DUKORAL for traveler's diarrhea), along with vaccine candidates targeting Lyme disease, chikungunya virus, and COVID-19. Valneva operates through segments including Commercialized Vaccines, Covid-19 Vaccine, Vaccine Candidates, and Technologies & Services. The company aims to address significant unmet medical needs in infectious diseases by leveraging its expertise and capabilities to advance vaccine candidates through clinical trials and ultimately commercialize them.

Aurion Biotechnologies is a clinical-stage biotech company focused on developing advanced therapies for ocular diseases, particularly those leading to blindness. Based in Seattle, Boston, and Tokyo, the company aims to transform the lives of millions by restoring vision through innovative cell therapies. Its lead candidate targets corneal edema and is one of the first clinically validated cell therapies in corneal care. The process involves culturing healthy cells from a donor cornea using a proprietary method, allowing cells from a single donor to potentially treat over 100 recipient eyes. Clinical trials in Japan have shown that patients experience significant and lasting improvements in corneal health indicators, including visual acuity and corneal thickness.

Vibliome Therapeutics, Inc. is a biotechnology company based in Bozeman, Montana, established in 2017. The company specializes in researching and developing non-hormonal birth control options for men, utilizing homeodomain-interacting protein kinase 4 (HIPK4). Additionally, Vibliome focuses on creating small molecule kinase inhibitors aimed at treating various cancers and inflammatory diseases. Their innovative approach involves a systematic methodology that enables the development of inhibitors with unique selectivity profiles, leveraging the extensive array of over 500 kinases present in the human genome. By analyzing the design of Type II inhibitors, Vibliome aims to lock kinase targets in an inactive conformation, facilitating the identification of unique similarities and differences between kinases, which supports the advancement of therapeutics for cancer and other chronic conditions.

The Oncology Institute of Hope and Innovation is a prominent community oncology practice in the United States, recognized for its comprehensive and integrated cancer care services. Established in 2007 and headquartered in Cerritos, California, the organization operates over 50 clinic locations across California, Arizona, and Nevada, employing more than 500 staff members, including over 80 physicians and advanced practice providers. The Oncology Institute specializes in cancer awareness, prevention, diagnosis, and treatment, offering services such as chemotherapy education, lab testing, pain management, and dietary counseling. It also features in-house facilities including an infusion center, pharmacy, and support groups, as well as the Hope, Health, and Healing Center, which provides alternative and holistic treatments. Additionally, the institute conducts clinical trials and provides educational seminars, aiming to deliver evidence-based care to over 1 million patients, thereby enhancing access to specialized oncology services in community settings.

Frontier Medicines Corporation, established in 2018 and headquartered in South San Francisco, California, is a pre-clinical stage biopharmaceutical company specializing in cancer research. The company employs chemoproteomics to discover and develop novel medicines targeting cancer-causing proteins. Frontier Medicines' innovative platform integrates advanced computational methods and machine learning algorithms to identify and pharmacologically target new binding pockets on proteins, thereby enabling small-molecule drug discovery and development for previously inaccessible targets.

Synthekine Inc. is a biotechnology company based in Menlo Park, California, specializing in the development of engineered cytokine therapies and immunotherapies aimed at treating cancer and autoimmune disorders. Founded in 2018, Synthekine utilizes advanced platform technologies, including engineered partial agonists and orthogonal cell therapies, to enhance the efficacy of cytokines while minimizing their toxic side effects. The company's innovative Synthekine Platform employs surrogate agonists instead of traditional mutant cytokines to create selective immunotherapies. Its product pipeline features candidates such as STK-009, an orthogonal ligand paired with SYNCAR-001, an orthogonal receptor-modified CAR-T therapy targeting CD-19. Additionally, Synthekine is developing STK-012, partial agonists of IL-2, and other novel immunotherapies that integrate cytokine receptors to initiate new signaling pathways without relying on wild-type cytokines.

Singular Genomics is a life science technology company that develops innovative sequencing platforms. Its core product, the Singular Sequencing Engine, powers two integrated solutions: G4 for next-generation sequencing (NGS) markets, offering high accuracy and speed; and PX, which combines single-cell analysis, spatial analysis, genomics, and proteomics in one versatile multi-omics instrument. These products aim to empower researchers and clinicians across diverse fields such as basic biology, oncology, immunology, and more.

Adaptive Phage Therapeutics, Inc. is a clinical-stage company focused on addressing the global challenge posed by multi-drug resistant (MDR) pathogenic bacteria. Founded in 2016 and headquartered in Gaithersburg, Maryland, the company offers therapeutic solutions utilizing its PhageBank, a comprehensive collection of bacteriophages—viruses that specifically target harmful bacteria. Through an advanced system for matching these phages to the unique bacterial infections of patients, Adaptive Phage Therapeutics aims to enable medical researchers to create effective treatments that can detect and combat MDR infections.

Jaguar Gene Therapy is a clinical-stage biotechnology company focused on accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company specializes in developing treatments that target nonworking or missing genes by introducing healthy copies back into the body to restore function. This approach aims to address significant unmet needs in healthcare by expediting the development of gene therapies from research to clinical application as safely and quickly as possible.

Jaguar Gene Therapy is a clinical-stage biotechnology company focused on accelerating breakthroughs in gene therapy for patients suffering from severe genetic diseases. The company specializes in developing treatments that target nonworking or missing genes by introducing healthy copies back into the body to restore function. This approach aims to address significant unmet needs in healthcare by expediting the development of gene therapies from research to clinical application as safely and quickly as possible.

Werewolf Therapeutics, Inc. is a biotechnology company based in Cambridge, Massachusetts, focused on developing innovative receptor agonists for cancer immunotherapy. Founded in 2017, the company is dedicated to creating therapeutics that stimulate the body’s immune system to combat cancer. Utilizing its proprietary PREDATOR platform, Werewolf designs conditionally activated molecules known as INDUKINE, which are engineered to remain inactive in peripheral tissues while selectively activating within the tumor microenvironment. This approach aims to overcome the limitations of traditional proinflammatory immune therapies, enhancing both adaptive and innate immunity to improve cancer treatment outcomes.

Neomorph, Inc. is a biotechnology company based in San Diego, California, founded in 2020. It specializes in developing innovative protein degradation solutions, particularly focusing on molecular glue degraders. This technology allows the company to repurpose cellular machinery to target and eliminate proteins associated with various diseases, particularly those deemed "undruggable." By leveraging molecular glue technology, Neomorph aims to discover and develop new medicines that address critical health challenges, thereby advancing the field of targeted protein degradation and supporting clinical development initiatives.

Encodia, Inc. is a biotechnology company based in San Diego, California, founded in 2015. The company specializes in proteomics research, providing innovative solutions for protein analysis through its proprietary technology. Encodia's platform utilizes a novel reverse-translation process that converts peptide sequence information into a DNA library, facilitating scalable and efficient protein sequencing. This technology allows researchers to gain comprehensive insights into cellular processes, thereby advancing personalized medicine and accelerating the discovery of novel approaches to address complex diseases. By democratizing protein sequencing, Encodia aims to enhance the capabilities of scientists in their pursuit of understanding the proteome.

Bridge Medicines LLC is a biotechnology company specializing in drug discovery and development. Founded in 2016 and based in New York, it aims to translate academic research into effective therapeutics for various human diseases. The company focuses on developing innovative treatments, including inhibitors for ENL-YEATS to target acute leukemias and small molecule inhibitors for activated factor XII to address hereditary angioedema and inflammatory disorders. Bridge Medicines collaborates with notable institutions such as Memorial Sloan Kettering Cancer Center and The Rockefeller University, providing comprehensive support from preclinical studies to clinical trials. By streamlining the path from concept to drug candidate, Bridge Medicines seeks to efficiently develop new therapies in oncology, neuropsychiatry, and other rare diseases, ultimately enhancing treatment options for physicians and patients.

Olema Oncology is a preclinical biotechnology company dedicated to developing innovative therapies for the treatment and prevention of estrogen receptor-positive breast cancer. The company specializes in discovering and commercializing targeted treatments specifically designed for women's cancers. By leveraging its extensive understanding of endocrine-driven cancers, nuclear receptors, and mechanisms of acquired resistance, Olema aims to create compounds that surpass existing therapies. The company's focus is on transforming the standard of care for both pre- and post-menopausal women with cancer, with an emphasis on developing more effective and convenient treatment options. Olema's pipeline includes drug candidates such as OP-1250 and OP-3136, which have progressed through discovery and preclinical studies.

Great Lakes Discoveries fosters preclinical and commercial clinical development to catalyze translational research initiatives. The company's new exploratory biologics initiative aims to develop a therapeutic treatment for systemic inflammation. Great Lakes Discovery is a product of the collaboration of Deerfield Management and the University of Michigan.

Generation Bio Co. is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies aimed at treating both rare and prevalent diseases. Founded in 2016 and formerly known as Torus Therapeutics, the company focuses on creating durable and redosable treatments for conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. Generation Bio employs a proprietary platform that utilizes closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP) to achieve targeted delivery of genetic materials across various tissues. This approach is designed to enhance treatment efficacy while expanding access to therapies for rare diseases and addressing more common conditions through scalable manufacturing processes.

Neomorph, Inc. is a biotechnology company based in San Diego, California, founded in 2020. It specializes in developing innovative protein degradation solutions, particularly focusing on molecular glue degraders. This technology allows the company to repurpose cellular machinery to target and eliminate proteins associated with various diseases, particularly those deemed "undruggable." By leveraging molecular glue technology, Neomorph aims to discover and develop new medicines that address critical health challenges, thereby advancing the field of targeted protein degradation and supporting clinical development initiatives.

Civetta Therapeutics, established in 2018 and headquartered in Cambridge, Massachusetts, focuses on developing small molecule therapeutics by targeting propeller proteins. These proteins are structural scaffolds that mediate protein-protein interactions and play diverse roles in various diseases, including cancer, neurodegeneration, and metabolic disorders. The company aims to create a portfolio of therapeutics by leveraging expertise in biochemistry, biology, and medicinal chemistry to target beta-propeller domains, with the goal of advancing new medicines for cancer and other diseases.

Frequency Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to repairing or reversing damage caused by degenerative diseases through its innovative Progenitor Cell Activation approach. This method utilizes a combination of small molecules to activate progenitor cells in the body, which facilitates the creation of functional tissue without the complexities of genetic engineering. The company’s lead product candidate, FX-322, is currently undergoing phase 2a clinical trials aimed at treating the underlying causes of sensorineural hearing loss. In addition to FX-322, Frequency Therapeutics is exploring treatments for various degenerative conditions, including multiple sclerosis and diseases affecting muscle, the gastrointestinal tract, skin, and bone. Established in 2014 and based in Woburn, Massachusetts, Frequency Therapeutics has established a collaboration agreement with Astellas Pharma Inc. for the development and commercialization of FX-322.

Frontier Medicines Corporation, established in 2018 and headquartered in South San Francisco, California, is a pre-clinical stage biopharmaceutical company specializing in cancer research. The company employs chemoproteomics to discover and develop novel medicines targeting cancer-causing proteins. Frontier Medicines' innovative platform integrates advanced computational methods and machine learning algorithms to identify and pharmacologically target new binding pockets on proteins, thereby enabling small-molecule drug discovery and development for previously inaccessible targets.

Stelexis Therapeutics, LLC is a biotechnology company dedicated to researching, discovering, and developing innovative therapies for cancer treatment. Founded in 2017 and based in New York, the company utilizes a proprietary drug discovery platform to identify pre-cancerous stem and progenitor cells that contribute to the development of primary and recurrent tumors. By focusing on therapeutics that selectively target pre-cancerous events, Stelexis aims to address both hematopoietic malignancies, such as acute myeloid leukemia, and solid tumors. The company's approach is centered on enabling therapeutic interventions and preventing relapses, positioning it as a key player in the field of cancer therapeutics.

Schrödinger is a healthcare-focused software company that specializes in computational drug design, serving pharmaceutical and biotechnology research sectors. Established in 1990, it offers a powerful computational platform that aids biopharmaceutical and industrial companies, as well as academic and government institutions, in their research efforts globally. Schrödinger operates through two main segments: Software and Drug Discovery. The Software segment supplies solutions aimed at enhancing the drug discovery process across the life sciences and materials science industries. Meanwhile, the Drug Discovery segment generates revenue through a portfolio of preclinical and clinical programs, both independently and through collaborative efforts. The company is committed to advancing science and talent to support its platform and has over 400 employees, engaging with customers and collaborators in more than 70 countries.

Cabaletta Bio, Inc. is a clinical-stage biotechnology company based in Philadelphia, Pennsylvania, specializing in the development of engineered T cell therapies for B cell-mediated autoimmune diseases. Utilizing its proprietary chimeric autoantibody receptor (CAAR) technology, the company designs T cells that selectively target and eliminate pathogenic B cells responsible for producing disease-causing autoantibodies, while preserving healthy B cells. The company's lead candidate, DSG3-CAART, is currently undergoing Phase I clinical trials for the treatment of mucosal pemphigus vulgaris, a severe autoimmune skin condition, as well as Hemophilia A with Factor VIII alloantibodies. In addition to DSG3-CAART, Cabaletta is advancing several other product candidates, including MuSK-CAART for myasthenia gravis and FVIII-CAART for a subset of Hemophilia A patients. The company collaborates with the University of Pennsylvania and has research agreements with The Regents of the University of California. Founded in 2017, Cabaletta Bio was previously known as Tycho Therapeutics, Inc. before rebranding in August 2018.

Tris Pharma, Inc. is a specialty pharmaceutical company based in Monmouth Junction, New Jersey, that engages in the research, development, manufacturing, and marketing of a diverse range of over-the-counter and prescription products. Founded in 2000, the company specializes in creating extended-release formulations tailored for children, seniors, and adults who have difficulty swallowing pills. Tris Pharma employs innovative technologies, including OralXR+ for gradual drug delivery, Nobuse for abuse-resistant formulations, and Lipisol, eXsol, and maxsol for various drug solubility challenges. Its product pipeline includes offerings for cough and cold, pain management, and neurological disorders, available in multiple dosage forms such as suspensions, chewable tablets, and orally disintegrating tablets. With a robust portfolio of over 30 granted patents and a commitment to pediatric and specialty generics, Tris Pharma continues to advance its position in the pharmaceutical market.

Pinnacle Hill is a biopharmaceutical company formed through a partnership between the University of North Carolina at Chapel Hill and Deerfield Management. The company is focused on discovering and developing new therapeutic drugs to address critical unmet medical needs, particularly for diseases such as multiple myeloma and Angelman syndrome. Pinnacle Hill aims to create innovative treatments that target the faulty UBE3A gene, either by replacing it or reactivating it in affected nerve cells. With financial backing and drug development expertise from Deerfield Management, Pinnacle Hill is dedicated to advancing promising research initiatives at UNC-Chapel Hill, thereby contributing to the healthcare industry’s ability to provide new treatment options for patients facing serious health challenges.

Epic Sciences, Inc. is a diagnostics company based in San Diego, California, focused on improving cancer management through the development of highly sensitive tests that identify and characterize circulating tumor cells (CTCs) using minimally invasive blood samples. Founded in 2008, the company’s platform enables the profiling of single-cell phenotypes and genotypes, providing detailed information on biomarker expression levels, morphologic characteristics, and genetic changes. Epic Sciences offers the Oncotype DX AR-V7 Nucleus Detect test specifically for patients with metastatic castration-resistant prostate cancer, as well as biopharma solutions. The company collaborates with biotechnology and pharmaceutical firms, major cancer centers, and renowned research institutions, including the National Cancer Institute and the National Institutes of Health, to enhance personalized medicine and guide treatment decisions.

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing off-the-shelf, genetically engineered allogeneic T cell therapies for cancer treatment. The company's pipeline includes UCART19, in development for relapsed/refractory acute lymphoblastic leukemia, and several preclinical allogeneic CAR T therapies targeting various cancers. Allogene's approach uses gene editing and advanced manufacturing technologies to create a scalable, broader patient eligibility option compared to autologous therapies. Revenue is primarily generated through collaborations and licensing agreements.

Ablexis, LLC is a biotechnology company based in San Francisco, California, founded in December 2009. The company specializes in human antibody drug discovery and development through its innovative AlivaMab Mouse platform, a transgenic mouse system designed to enhance the efficiency of discovering therapeutic antibodies for human diseases. Ablexis aims to facilitate the development of next-generation antibody drugs by offering its platform to biotechnology and pharmaceutical companies through strategic partnerships, thereby significantly improving the discovery process compared to traditional methods.

Lakeside Discovery is an innovative drug discovery collaboration leveraging Northwestern’s most promising biomedical research and Deerfield’s strategic expertise to develop life-changing medicines.

Ancora Innovation is a collaborative enterprise that combines the life science discovery initiatives from Vanderbilt University with Deerfield's focus on advancing drug development. The company is dedicated to accelerating the creation of early-stage therapeutics that are rooted in innovative biological research. Ancora Innovation aims to identify promising drug candidates and establish comprehensive development plans to bring these novel therapeutics to market. Additionally, it supports the growth of successful start-up companies that emerge from its research efforts, providing essential funding to facilitate transformative advancements in the pharmaceutical field.

Dracen Pharmaceuticals, Inc. is a biopharmaceutical company based in Baltimore, Maryland, focused on discovering and developing innovative anticancer therapies. Founded in 2016, the company specializes in a class of treatments known as novel glutamine antagonists, which possess direct anti-tumor properties and enhance the immune system's ability to combat cancer. These therapies aim to remodel the tumor microenvironment, making it more responsive to immuno-oncology approaches. By increasing the number of patients who respond to cancer treatments and extending survival rates, Dracen Pharmaceuticals seeks to improve outcomes for cancer patients, particularly in challenging areas that have previously evaded effective immuno-oncology strategies.

Generation Bio Co. is a genetic medicines company based in Cambridge, Massachusetts, that specializes in developing innovative gene therapies aimed at treating both rare and prevalent diseases. Founded in 2016 and formerly known as Torus Therapeutics, the company focuses on creating durable and redosable treatments for conditions affecting the liver, retina, skeletal muscle, central nervous system, and oncology. Generation Bio employs a proprietary platform that utilizes closed-ended DNA (ceDNA) and a cell-targeted lipid nanoparticle delivery system (ctLNP) to achieve targeted delivery of genetic materials across various tissues. This approach is designed to enhance treatment efficacy while expanding access to therapies for rare diseases and addressing more common conditions through scalable manufacturing processes.

Broad Institute brings together a diverse group of individuals from across its partner institutions — undergraduate and graduate students, postdoctoral fellows, professional scientists, administrative professionals, and academic faculty.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

Chondrial Therapeutics LLC is a clinical-stage biotechnology company based in Indianapolis, Indiana, specializing in the discovery and development of orphan drugs for mitochondrial diseases. Founded in 2013, the company is particularly focused on advancing treatments for rare conditions such as Friedreich’s Ataxia. Through its commitment to scientific research, Chondrial Therapeutics aims to address unmet medical needs in the field of mitochondrial disorders.

Bridge Medicines LLC is a biotechnology company specializing in drug discovery and development. Founded in 2016 and based in New York, it aims to translate academic research into effective therapeutics for various human diseases. The company focuses on developing innovative treatments, including inhibitors for ENL-YEATS to target acute leukemias and small molecule inhibitors for activated factor XII to address hereditary angioedema and inflammatory disorders. Bridge Medicines collaborates with notable institutions such as Memorial Sloan Kettering Cancer Center and The Rockefeller University, providing comprehensive support from preclinical studies to clinical trials. By streamlining the path from concept to drug candidate, Bridge Medicines seeks to efficiently develop new therapies in oncology, neuropsychiatry, and other rare diseases, ultimately enhancing treatment options for physicians and patients.

Oncorus, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, dedicated to developing innovative viral immunotherapies for cancer treatment. The company's lead product candidate, ONCR-177, utilizes an oncolytic herpes simplex virus type 1 platform and is currently undergoing Phase I clinical trials to assess its efficacy against various cancers. In addition to ONCR-177, Oncorus is advancing its ONCR-GBM program aimed at treating brain cancer, along with synthetic viral immunotherapies derived from Coxsackievirus A21 and Seneca Valley Virus. The company has established a clinical trial collaboration with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 in combination with Merck’s KEYTRUDA immunotherapy. Founded in 2015, Oncorus is committed to improving patient outcomes and has pledged to contribute a portion of its product sales to support cancer research and care in developing regions.

Synlogic, Inc. is a clinical-stage biopharmaceutical company based in Cambridge, Massachusetts, specializing in the development of synthetic biotic medicines aimed at treating metabolic, inflammatory, and cancer-related diseases. The company’s lead therapeutic program, SYNB1618, is currently undergoing Phase I/IIa clinical trials for the treatment of phenylketonuria, a rare genetic metabolic disorder. Additionally, Synlogic is advancing SYNB1891, an intratumoral synthetic biotic medicine in Phase I clinical trials targeting solid tumors and lymphoma. The company employs a proprietary approach that utilizes engineered probiotics, specifically Escherichia coli Nissle 1917, to create GI-restricted oral therapies that are non-colonizing and reversible, facilitating easier administration and storage. Synlogic is also exploring treatments for other conditions, including secondary hyperoxaluria, inflammatory bowel disease, and various metabolic disorders, and has established a collaboration with Ginkgo Bioworks to further its development efforts.

Syros Pharmaceuticals, Inc. is a biopharmaceutical company based in Cambridge, Massachusetts, that specializes in developing innovative treatments for cancer and monogenic diseases through gene control medicines. The company is advancing its lead product candidates, including SY-1425, a selective retinoic acid receptor alpha agonist currently in Phase II clinical trials for specific patient populations with acute myeloid leukemia and myelodysplastic syndrome, and SY-5609, a cyclin-dependent kinase 7 inhibitor under investigation in a Phase I clinical trial for advanced solid tumors. Syros is also engaged in collaborative research, including a partnership with Incyte Corporation aimed at identifying therapeutic targets for myeloproliferative neoplasms and a licensing agreement with TMRC Co. Ltd. for the development of tamibarotene. With a focus on mapping gene regulatory circuits, Syros leverages its proprietary platform and expertise to address significant unmet medical needs in oncology. Founded in 2011, the company aims to establish new standards of care for patients with hematologic malignancies.

AveXis, operating as Novartis Gene Therapies, Inc., is a biotechnology company focused on developing and commercializing gene therapies for rare and life-threatening neurological genetic diseases. Acquired by Novartis in 2018, the company specializes in innovative treatments such as motor neuron cell-targeted gene replacement therapy aimed at conditions like spinal muscular atrophy, Rett syndrome, and amyotrophic lateral sclerosis. These therapies are designed to assist healthcare institutions in addressing diseases that cause progressive muscle weakness, paralysis, and ultimately, death. Through its advancements in gene therapy, AveXis is dedicated to improving the lives of patients and families impacted by these severe genetic disorders.

AveXis, operating as Novartis Gene Therapies, Inc., is a biotechnology company focused on developing and commercializing gene therapies for rare and life-threatening neurological genetic diseases. Acquired by Novartis in 2018, the company specializes in innovative treatments such as motor neuron cell-targeted gene replacement therapy aimed at conditions like spinal muscular atrophy, Rett syndrome, and amyotrophic lateral sclerosis. These therapies are designed to assist healthcare institutions in addressing diseases that cause progressive muscle weakness, paralysis, and ultimately, death. Through its advancements in gene therapy, AveXis is dedicated to improving the lives of patients and families impacted by these severe genetic disorders.

Zevra Therapeutics is a development-stage biopharmaceutical company focused on creating new therapies for pain, ADHD, and other central nervous system (CNS) diseases, particularly in the realm of rare diseases. The company is dedicated to developing safer, abuse-resistant opioid pain relievers and employs a proprietary Ligand Activated Therapy (LAT) approach to drug discovery and development. This innovative platform allows Zevra to enhance existing medications and streamline the development process while preserving strong intellectual property rights. By integrating scientific research with patient needs and data-driven strategies, Zevra Therapeutics aims to address the challenges of drug development, delivering transformational therapies for conditions with limited or no treatment options.

Spark Therapeutics, Inc. is a biotechnology company focused on developing gene therapy products aimed at treating debilitating genetic diseases. Headquartered in Philadelphia, Pennsylvania, the company was founded in 2013 and has established itself as a leader in the field of gene therapy, with a robust pipeline that includes LUXTURNA for retinal dystrophy, as well as several candidates for hemophilia and choroideremia. Spark is also exploring therapies for neurodegenerative diseases and inherited retinal diseases. The company holds a collaboration agreement with Pfizer for the development of hemophilia B treatments and has partnered with Novartis for the commercialization of its lead product outside the United States. Spark Therapeutics leverages a proprietary manufacturing platform and a team with extensive expertise in research, clinical development, and regulatory affairs, building on a legacy of innovation in gene therapy from its origins at The Children’s Hospital of Philadelphia. As of December 2019, Spark operates as a subsidiary of Roche Holding AG.

Infinity Pharmaceuticals is a clinical-stage biotechnology company focused on developing innovative therapies for cancer treatment. Its lead product, eganelisib, is an oral immuno-oncology agent designed to reprogram macrophages and address immune suppression in cancer. Infinity is conducting multiple clinical studies, including the global MARIO-275 trial, which investigates eganelisib in combination with Opdivo® for patients with urothelial cancer. The company is also exploring eganelisib in various combinations for front-line treatment in advanced cancers, including triple-negative breast cancer and renal cell carcinoma, evaluating it alongside other therapeutics such as Tecentriq® and Abraxane®. Additionally, Infinity is collaborating with Arcus Biosciences to assess a novel regimen combining eganelisib with etrumadenant and Doxil® in advanced triple-negative breast cancer patients. The company is committed to developing treatments for various hematologic malignancies and solid tumors, leveraging its strategic partnerships to advance its oncology programs.

Kolltan Pharmaceuticals, Inc. is a clinical-stage biotechnology company founded in 2007 and based in New Haven, Connecticut. The company specializes in the discovery and development of monoclonal antibody drugs that target receptor tyrosine kinases (RTKs), which play a crucial role in various cancers and other diseases. Its lead product candidate, KTN3379, is an antibody targeting the ErbB3 RTK and is currently undergoing Phase I clinical trials for adult patients with advanced solid tumors. Additionally, Kolltan is developing KTN0158, a KIT RTK inhibitor aimed at treating neurofibromatosis type 1 and other inflammatory conditions, as well as KIT-ADC, an antibody-drug conjugate for oncology applications. The company is also engaged in various research programs focused on RTK targets, building on foundational discoveries made in collaboration with leading academic laboratories. As of late 2016, Kolltan Pharmaceuticals operates as a subsidiary of Celldex Therapeutics, Inc.

Intra-Cellular Therapies, Inc. is a biopharmaceutical company based in New York that focuses on developing innovative treatments for neuropsychiatric and neurologic diseases, as well as other central nervous system (CNS) disorders. The company’s lead drug candidate, CAPLYTA, is designed to treat schizophrenia and bipolar disorder, along with behavioral disturbances associated with dementia and autism. Additionally, Intra-Cellular Therapies is working on several other drug candidates, including ITI-002, which targets phosphodiesterase type 1; ITI-214 for Parkinson’s disease; and ITI-333 for substance use disorders, pain, and related psychiatric conditions. The company employs a multidisciplinary approach that combines the expertise of medicinal scientists, pharmacologists, and clinical development scientists to create novel therapies. Intra-Cellular Therapies also utilizes its CNSProfile technology platform to generate molecular signatures for drug compounds, aiding in drug discovery and development, and has engaged in collaborations to investigate antidotes for chemical warfare agents.

Pacific Biosciences specializes in human, microbial, plant, and animal genomics, focusing on areas such as infectious disease research. The company designs and manufactures sequencing systems that address complex genetic challenges, utilizing its innovative single molecule real-time (SMRT) sequencing technology to detect biological processes in real time. Its product offerings include the PacBio RS II and Sequel Systems, which facilitate the monitoring and analysis of biochemical reactions at the single-molecule level, along with consumables like SMRT cells and various reagent kits. Customers range from research institutions and commercial laboratories to pharmaceutical and agricultural companies, with sales conducted through direct channels in North America and Europe, and distribution partners in Asia, the Middle East, and Latin America. Founded in 2000 and headquartered in Menlo Park, California, Pacific Biosciences continues to advance genomics research and applications.

Nektar Therapeutics is a biopharmaceutical company based in San Francisco, California, with additional operations in Huntsville, Alabama, and Hyderabad, India. The company focuses on researching and developing investigational drugs for oncology, immunology, and virology, alongside a portfolio of partnered approved medicines. Its clinical pipeline includes notable candidates such as NKTR-181 for chronic low back pain, ONZEALD for advanced metastatic breast cancer, and Bempegaldesleukin, designed to enhance cancer-killing T cell activity. Nektar is also developing therapies for autoimmune diseases, including NKTR-358, and various other conditions like hemophilia A, opioid-induced constipation, and systemic lupus erythematosus. The company's strategy involves leveraging the immune system to combat cancer and restore immune balance in autoimmune disorders. Nektar has established collaboration agreements with several major pharmaceutical companies, enhancing its research capabilities and development efforts. Incorporated in 1990, Nektar Therapeutics continues to advance its innovative drug candidates through various stages of clinical trials.

Tesaro, Inc. is an oncology-focused biopharmaceutical company established in 2010 and headquartered in Waltham, Massachusetts. The company is dedicated to developing and commercializing cancer therapeutics and supportive care products. Its primary offerings include ZEJULA, a potent oral poly polymerase inhibitor for the maintenance treatment of recurrent ovarian, fallopian tube, or primary peritoneal cancer, and VARUBI, a neurokinin-1 receptor antagonist designed to prevent chemotherapy-induced nausea and vomiting. Additionally, Tesaro is engaged in the development of several immunotherapy antibody candidates, including TSR-042, TSR-022, and TSR-033, all currently in phase I clinical trials. The company collaborates with various organizations, such as AnaptysBio, Janssen Biotech, and Merck Sharp & Dohme, to enhance its research and development efforts. Tesaro aims to leverage its management team's expertise to identify and commercialize innovative treatments that improve the lives of cancer patients. As of January 2019, Tesaro operates as a subsidiary of GlaxoSmithKline.

WaferGen Bio-systems, Inc. is an emerging genomic analysis company in the early stage of commercialization. The company offers the transformative SmartChip Real-Time PCR System—a next-generation Real-Time PCR System for profiling and validation of gene expression patterns (biomarkers) on a single platform. The SmartChip System provides a range of high-throughput capabilities including microRNA and mRNA gene expression profiling and single nucleotide polymorphism (SNP) genotyping.

Cytokinetics is a late-stage biopharmaceutical company dedicated to discovering, developing, and commercializing innovative treatments that target muscle function. The company focuses on developing muscle activators and inhibitors for conditions characterized by reduced muscle performance, weakness, and fatigue, including diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary disease. Utilizing small molecules specifically engineered to enhance muscle function and contractility, Cytokinetics aims to create investigational medicines that may improve the health span of individuals affected by serious cardiovascular and neuromuscular disorders.

Vescor Therapeutics is a biopharmaceutical company focused on developing autophagy-targeted therapeutics to aid in cancer treatment. The company conducts clinical studies that demonstrate the essential role of autophagy in sustaining tumor growth and providing insights into mechanisms of resistance against existing therapies. Vescor Therapeutics specializes in creating small molecule inhibitors that target key proteins involved in the autophagy cascade, thereby enhancing metabolic flexibility for cancer patients. This approach aims to help patients meet their energy needs and cellular requirements, potentially improving treatment outcomes in oncology.

Pacific Biosciences specializes in human, microbial, plant, and animal genomics, focusing on areas such as infectious disease research. The company designs and manufactures sequencing systems that address complex genetic challenges, utilizing its innovative single molecule real-time (SMRT) sequencing technology to detect biological processes in real time. Its product offerings include the PacBio RS II and Sequel Systems, which facilitate the monitoring and analysis of biochemical reactions at the single-molecule level, along with consumables like SMRT cells and various reagent kits. Customers range from research institutions and commercial laboratories to pharmaceutical and agricultural companies, with sales conducted through direct channels in North America and Europe, and distribution partners in Asia, the Middle East, and Latin America. Founded in 2000 and headquartered in Menlo Park, California, Pacific Biosciences continues to advance genomics research and applications.

Nivalis Therapeutics is a biotechnology company focused on developing innovative disease-modifying therapies aimed at cystic fibrosis (CF). The company is particularly dedicated to preserving intracellular S-nitrosoglutathione (GSNO), a naturally occurring molecule that plays a crucial role in cell signaling and is linked to the pathophysiology of CF. Its lead therapeutic candidate, N91115, specifically targets patients with the F508del mutation, which is the most prevalent mutation responsible for cystic fibrosis. Founded in 2007 and based in Boulder, Colorado, Nivalis Therapeutics aims to significantly improve the quality of life for individuals affected by cystic fibrosis and their families.

BioSante Pharmaceuticals, Inc. (BioSante) is a specialty pharmaceutical company focused on developing products for female sexual health, menopause, contraception and male hypogonadism. The Company's products for female sexual health, menopause, contraception and male hypogonadism include LibiGel, a once daily transdermal testosterone gel in Phase III clinical development under a special protocol assessment (SPA) for the treatment of female sexual dysfunction (FSD); Elestrin, a once daily transdermal estradiol (estrogen) gel indicated for the treatment of moderate-to-severe vasomotor symptoms; The Pill-Plus (triple component contraceptive), a once daily use of various combinations of estrogens, progestogens and androgens in development for the treatment of female sexual dysfunction (FSD) in women using oral or transdermal contraceptives, and Bio-T-Gel, a once daily transdermal testosterone gel in development for the treatment of hypogonadism, or testosterone deficiency, in men.

Array BioPharma is a biopharmaceutical company dedicated to the discovery, development, and commercialization of targeted small molecule drugs for the treatment of cancer and other significant diseases. Founded in 1998 and headquartered in Boulder, Colorado, the company focuses on clinical-stage drugs, including binimetinib, encorafenib, selumetinib, tucatinib, and several others. Array BioPharma has established partnerships with major pharmaceutical companies, such as AstraZeneca and Roche, to enhance its drug development and commercial capabilities. The company operates across North America, Europe, and the Asia Pacific, underscoring its commitment to providing innovative therapies for patients in need.

Pacific Biosciences specializes in human, microbial, plant, and animal genomics, focusing on areas such as infectious disease research. The company designs and manufactures sequencing systems that address complex genetic challenges, utilizing its innovative single molecule real-time (SMRT) sequencing technology to detect biological processes in real time. Its product offerings include the PacBio RS II and Sequel Systems, which facilitate the monitoring and analysis of biochemical reactions at the single-molecule level, along with consumables like SMRT cells and various reagent kits. Customers range from research institutions and commercial laboratories to pharmaceutical and agricultural companies, with sales conducted through direct channels in North America and Europe, and distribution partners in Asia, the Middle East, and Latin America. Founded in 2000 and headquartered in Menlo Park, California, Pacific Biosciences continues to advance genomics research and applications.

Array BioPharma is a biopharmaceutical company dedicated to the discovery, development, and commercialization of targeted small molecule drugs for the treatment of cancer and other significant diseases. Founded in 1998 and headquartered in Boulder, Colorado, the company focuses on clinical-stage drugs, including binimetinib, encorafenib, selumetinib, tucatinib, and several others. Array BioPharma has established partnerships with major pharmaceutical companies, such as AstraZeneca and Roche, to enhance its drug development and commercial capabilities. The company operates across North America, Europe, and the Asia Pacific, underscoring its commitment to providing innovative therapies for patients in need.

Third Wave Technologies, Inc. specializes in developing and marketing molecular diagnostic products that facilitate DNA and RNA analysis for various medical applications. The company provides innovative solutions for physicians and researchers to improve disease analysis and treatment. Utilizing its proprietary Invader chemistry, Third Wave's products are used across several segments, including women's health, infectious diseases, genetics, pharmacogenetics, and oncology. The company offers in vitro diagnostic devices and analyte specific reagents, enabling laboratories to conduct assays for hepatitis C virus genotyping, inherited disorders, and other genetic mutations. Additionally, Third Wave develops products for research and agricultural biotechnology markets, serving a diverse customer base that includes clinical laboratories, pharmaceutical and biotechnology firms, academic institutions, and healthcare providers. Founded in 1993 and headquartered in Madison, Wisconsin, Third Wave operates as a subsidiary of Hologic Inc. as of July 2008.

CymaBay Therapeutics, Inc., established in 1988 and headquartered in Newark, California, is a clinical-stage biopharmaceutical company dedicated to developing therapies for liver diseases and other chronic conditions with significant unmet medical needs. Its primary focus is on seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, currently in Phase II trials for treating primary biliary cholangitis, sclerosing cholangitis, and nonalcoholic steatohepatitis. Additionally, the company is developing MBX-2982, an orally-active G protein-coupled receptor agonist targeting gut/liver diseases, and CB-001, a preclinical-stage product candidate for treating gut/liver disease using omega-3 fatty acids. CymaBay has partnerships with Janssen Pharmaceuticals and DiaTex for developing therapies for metabolic diseases and gout, respectively.